Premium Price Target: $44 (30% upside)

Intellia: Is Gene Editing The Future of Medicine?

9 days ago

Premium

Eli Lilly's Chronic Pincer Move

More than a month ago

Premium Price Target: $554 (18% upside)

Elevance Health: Profiting from the Wealthiest Generation

More than a month ago

Premium

Shockwave: The Sleeper in Biotech

3 months ago

Premium

Evotec: The Best AI Healthcare Play

3 months ago

Premium Price Target: $88 (19% upside)

AstraZeneca's AI Cancer Missiles

5 months ago

Premium Price Target: $483 (15% upside)

How Eli Lilly is Abolishing Obesity

5 months ago

Premium Price Target: $140 (21% upside)

Merck's Secret Weapon Against Cancer

5 months ago

Premium Price Target: $340 (16% upside)

Intuitive Surgical: The Right Growth at the Right Time

5 months ago

Premium

Illumina: A Famous Activist Coming Aboard

6 months ago

Premium

Zoetis: Diversified and Poised for Growth

6 months ago

Premium

Merck: Getting Closer To Solving Cancer

10 months ago

Premium

Intuitive Surgical: A Strong Return to Medical Normal

10 months ago

Premium

Eli Lilly: The Biggest Healthcare Advancement In A Decade

10 months ago

Premium

Illumina is About to Corner the DNA Market

11 months ago

Premium

Biogen: A Crossroads to Complete our Pharma Trifecta

More than 1 year ago

Premium Price Target: $388 (28% upside)

Eli Lilly: A Solid Discount Before the Big Show

More than 1 year ago

Premium Price Target: $689 (21% upside)

Thermo Fischer Scientific: Pivoting to Growth

More than 1 year ago

Premium Price Target: $342 (20% upside)

Eli Lilly: Defeating America's Biggest Health Crisis

More than 1 year ago

Premium Price Target: $105 (24% upside)

Merck: Medical Breakthrough After Breakthrough

More than 1 year ago

Premium Price Target: $22 (23% upside)

Bayer: Pulling Out of an 8-Year Dip

More than 1 year ago

Premium Price Target: $262 (38% upside)

Zoetis: A Unique Healthcare Company Focused On Animals & Livestock

More than 1 year ago

Premium Price Target: $72.50 (25% upside)

GE Healthcare: Covering The New IPO

More than 1 year ago

Premium Price Target: At least 4-5x from here

How this Biotech is Reinventing the World through Coding

More than 1 year ago